Prognostic role of plasma mammaglobin A expression in breast carcinoma patients: a meta-analysis

Abstract

Mammaglobin A expression in peripheral blood (PB) of breast carcinoma patients has been evaluated by various studies, but the findings have been inconsistent. This meta-analysis aimed to clarify the prognostic value of mammaglobin A in the PB of breast carcinoma patients and define its relationships with clinicopathological features. PubMed, EMBASE, and the Cochrane Library databases were systematically searched for eligible studies through September 26, 2017. A total of 20 studies involving 2,323 patients were analyzed, and the data were independently extracted by two researchers. The combined hazard ratios (HRs) with 95% CI was used to assess the association between survival data and plasma mammaglobin A expression, and odds ratios (ORs) and 95% CIs were used to assess the associations between clinicopathological parameters and plasma mammaglobin A expression. The results indicated that plasma mammaglobin A expression was a predictor of poor prognosis for breast carcinoma patients, with an HR of 2.08 (95% CI=1.48–2.91; P<0.0001) for overall survival. Moreover, plasma mammaglobin A was significantly associated with lymph node metastasis (OR=2.00; 95% CI=1.17–3.45; P=0.01) and advanced tumor stage (OR=3.01; 95% CI=1.57–5.77; P=0.0009) in breast carcinoma patients. However, the results revealed that plasma mammaglobin A was not significantly associated with tumor size (OR=1.29; 95% CI=0.46–3.66; P=0.63), tumor differentiation (OR=0.99; 95% CI=0.63–1.57; P=0.97), menopausal status (OR=0.75; 95% CI=0.48–1.18; P=0.22), estrogen receptor status (OR=0.78; 95% CI=0.44–1.36; P=0.38), progesterone receptor status (OR=0.76; 95% CI=0.57–1.02; P=0.07), or human epidermal growth factor receptor 2 status (OR=1.12; 95% CI=0.78–1.59; P=0.54). In conclusion, the results demonstrate that positive plasma mammaglobin A expression might serve as a biomarker of poor prognosis for breast carcinoma patients.

Nanoscale flow cytometry for immunophenotyping and quantitating extracellular vesicles in blood plasma

“…A meta-analysis of several studies revealed that higher levels of circulating mammaglobin-a in plasma correlates with lymph node metastasis and advanced tumor stage. [16][17][18][19] Furthermore, enzyme linked immunosorbent diagnostic assay (ELISA) has been used to show that secreted mammaglobin-a protein is elevated in breast cancer patient blood. 20 Predictive analysis of mammaglobin-a protein structure reveals a putative transmembrane domain suggesting that mammaglobin-a may be anchored at the plasma membrane on breast cells.…”

Microvessel Density and Mammaglobin A Expression as Prognostic Markers in Molecular Types of Breast Cancer

“…MVD, the major angiogenesis-related parameter [32] does not always correlate with MGB expression hence the difficulty of ensuring a complete estimation of the patients' prognosis. However, Hu et al [33] have demonstrated the implications of MGB-A as an independent prognostic biomarker in breast cancer. Plasma MGB-A is associated with lymph node metastases and advanced tumor stage, but no correlation was found between MGB-A and tumor size, tumor differentiation, menopausal status and hormone status of breast cancer patients [33].…”

“…However, Hu et al [33] have demonstrated the implications of MGB-A as an independent prognostic biomarker in breast cancer. Plasma MGB-A is associated with lymph node metastases and advanced tumor stage, but no correlation was found between MGB-A and tumor size, tumor differentiation, menopausal status and hormone status of breast cancer patients [33]. Our results show a variable MGB expression in the molecular types of breast cancer.…”

Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review

“…It has been described that MAG possesses specificity and high immunogenicity and also regulates the tumorigenesis and aggressiveness in BC by increasing the cellular proliferation, migration, and invasion of cancer cells. MAG is responsible for activating signaling pathways such as; MAPK, FAK, MMP, and NF-κB [103], and is involved in the expression of IL-2. In vitro experiments showed that positive cells to the expression of mammaglobin could promote the activation of CD4+ and CD8+ T cells capable of recognizing and lysate cancer cells [104].…”